Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

RXRong XieFujian Medical UniversityQHQiang HeAcademy of Medical SciencesLXLinna XieWuhan University of Technology

Discussion

Loading...

Member takes

Overview

Real-world data reveals POLA-Z-R improves overall response in super-elderly DLBCL patients, suggesting an effective alternative to chemoimmunotherapy.

Key Points

  • To evaluate the efficacy and safety of POLA-Z-R therapy in super-elderly patients with DLBCL.
  • Conducted a single-center, retrospective analysis of patients aged ≥82 with DLBCL
  • Collected data on clinico-pathological characteristics and treatment outcomes
  • Analyzed the Overall Response Rate and safety of the POLA-Z-R regimen.
  • Overall Response Rate was 87.5% with Complete Response at 37.5%
  • Patients displayed high-risk features with 87.5% in Ann Arbor stage IV disease
  • Median IPI score was 4.5 and most patients were treatment-naïve
  • Treatment was generally well-tolerated with manageable adverse events reported.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2b1https://doi.org/10.1182/blood-2025-7221
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates2025
  2. 2Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026
  3. 3Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study2025
  4. 4Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study2025 · 5 citations
  5. 5Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study2025